Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Revenue projections:

Revenue projections for TMO
Revenue projections for TMO

The projected decline in TMO's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.551000
forwardPE 21.411787
debtToEquity 80.575000
earningsGrowth 0.094000
revenueGrowth 0.105000
grossMargins 0.409880
operatingMargins 0.187510
trailingEps 18.560000
forwardEps 27.510080

Thermo Fisher Scientific Inc.'s current ratio of 1.551 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that Thermo Fisher Scientific Inc. is financially well-prepared to meet its liabilities without difficulty.
TMO's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
Thermo Fisher Scientific Inc.'s elevated debt-to-equity ratio suggests that the company is using significant debt to finance its operations. This level of leverage can amplify financial risk, particularly if profitability decreases or external conditions become unfavorable.
Thermo Fisher Scientific Inc.'s forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with Thermo Fisher Scientific Inc. anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for TMO
Price projections for TMO

Thermo Fisher Scientific Inc.'s price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.

Insider Transactions:

Insider Transactions for TMO
Insider Transactions for TMO


26 TMO stock sales were completed, with market price of 544.5050670917218.The period under consideration did not see any sell transactions.The higher number of buys versus sells near Thermo Fisher Scientific Inc.'s current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for TMO
Recommendations trend for TMO


Analysts have shown a buy bias for TMO, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to TMO, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.